Brokerages forecast that Kala Pharmaceuticals (NASDAQ:KALA) will post ($0.45) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Kala Pharmaceuticals’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.49). The company is scheduled to issue its next quarterly earnings report on Monday, June 25th.
On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($1.98) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.74). For the next year, analysts forecast that the company will post earnings of ($2.57) per share, with EPS estimates ranging from ($3.38) to ($1.93). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings data on Monday, March 26th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.09).
KALA has been the subject of several research reports. Wedbush reissued an “outperform” rating and set a $46.00 price objective on shares of Kala Pharmaceuticals in a research note on Friday, December 22nd. BidaskClub raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Wells Fargo reaffirmed a “buy” rating on shares of Kala Pharmaceuticals in a research report on Friday, January 5th. Finally, Zacks Investment Research raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $35.80.
Shares of KALA traded up $0.18 during trading hours on Friday, hitting $16.00. 193,093 shares of the company were exchanged, compared to its average volume of 327,168. The firm has a market cap of $393.88 and a PE ratio of -2.74. The company has a quick ratio of 7.97, a current ratio of 7.97 and a debt-to-equity ratio of 0.13. Kala Pharmaceuticals has a one year low of $11.81 and a one year high of $26.75.
In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc bought 75,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was acquired at an average price of $14.98 per share, with a total value of $1,123,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders bought 622,397 shares of company stock valued at $9,273,112.
Several institutional investors have recently modified their holdings of KALA. JPMorgan Chase & Co. acquired a new stake in Kala Pharmaceuticals during the third quarter valued at $4,037,000. Bank of New York Mellon Corp acquired a new stake in Kala Pharmaceuticals during the third quarter valued at $540,000. Farallon Capital Management LLC boosted its position in Kala Pharmaceuticals by 85.0% during the fourth quarter. Farallon Capital Management LLC now owns 185,000 shares of the company’s stock valued at $3,421,000 after purchasing an additional 85,000 shares during the last quarter. Emory University acquired a new stake in Kala Pharmaceuticals during the fourth quarter valued at $1,827,000. Finally, California State Teachers Retirement System acquired a new stake in Kala Pharmaceuticals during the third quarter valued at $301,000. 72.30% of the stock is owned by institutional investors and hedge funds.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.